These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36971065)

  • 1. Evaluation of the clinical features and laboratory data of patients with severe asthma classified as super-responder or non super-responder to omalizumab treatment: a single-center real-life study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    J Asthma; 2023 Oct; 60(10):1862-1868. PubMed ID: 36971065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the General Characteristics of Patients with Severe Asthma Who Switched from Omalizumab to Mepolizumab versus Patients Who Responded to Omalizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO
    Int Arch Allergy Immunol; 2024; 185(2):158-166. PubMed ID: 37992693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
    Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
    Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Omalizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Severe Allergic Asthma.
    Atayik E; Aytekin G; Aydin İ; Omeroglu E
    Iran J Allergy Asthma Immunol; 2024 May; 23(3):245-256. PubMed ID: 39422385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease].
    Sui HJ; Zhen Z; Wang QG; Cong TC; Huang JJ; Hu Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):273-280. PubMed ID: 36797588
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study.
    Tiotiu A; Oster JP; Roux PR; Nguyen Thi PL; Peiffer G; Bonniaud P; Dalphin JC; de Blay F
    J Investig Allergol Clin Immunol; 2020; 30(1):49-57. PubMed ID: 30931917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study.
    Bidder T; Sahota J; Rennie C; Lund VJ; Robinson DS; Kariyawasam HH
    Rhinology; 2018 Mar; 56(1):42-45. PubMed ID: 29288573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
    Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
    Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma.
    Özgen H; Tepetam FM; Bulut İ; Örçen C
    Tuberk Toraks; 2021 Mar; 69(1):39-48. PubMed ID: 33853304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
    Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
    J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
    Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps.
    Tiotiu A; Mendez-Brea P; Ioan I; Romero-Fernandez R; Oster JP; Hoang TC; Roux P; Ochoa-Gutierrez DC; Bonniaud P; de Blay F; Gonzalez-Barcala FJ
    Clin Rev Allergy Immunol; 2023 Apr; 64(2):179-192. PubMed ID: 35420388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No difference in omalizumab efficacy in patients with asthma by number of asthma-related and allergic comorbidities.
    Chen M; Choo E; Yoo B; Raut P; Haselkorn T; Pazwash H; Holweg CTJ; Hudes G
    Ann Allergy Asthma Immunol; 2021 Jun; 126(6):666-673. PubMed ID: 33465457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab Treatment in Uncontrolled Asthma and CRSwNP Patients, with Previous Endoscopic Sinus Surgery, to Improve Quality of Life and Endoscopic Outcomes: a Two-Year Real-Life Study.
    Maza-Solano J; Callejon-Leblic A; Martin-Jimenez D; Moreno-Luna R; Gonzalez-Garcia J; Cuvillo A; Sanchez-Gomez S
    Curr Allergy Asthma Rep; 2023 Oct; 23(10):555-566. PubMed ID: 37644255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
    Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
    Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Mepolizumab in Patients with Severe Eosinophilic Asthma with/without Nasal Polyposis: A Real-Life Study.
    Bravo-Gutiérrez FJ; Miralles-López JC; Valverde-Molina J; Alemany Francés ML; Andújar-Espinosa R; Castilla-Martínez M; Avilés-Inglés MJ; Mora-González A; Pajarón-Fernández MJ; Cabrejos-Perotti S; Meseguer-Arce J; Flores Martín I; Pérez-Fernández V;
    Int Arch Allergy Immunol; 2024; 185(3):253-259. PubMed ID: 38035559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?
    Arslan B; Paçacı Çetin G; Türk M; Gülmez İ; Yılmaz İ
    Int Arch Allergy Immunol; 2022; 183(10):1071-1077. PubMed ID: 35917798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung function parameters in omalizumab responder patients: An interesting tool?
    Paganin F; Mangiapan G; Proust A; Prudhomme A; Attia J; Marchand-Adam S; Pellet F; Milhe F; Melloni B; Bernady A; Raspaud C; Nocent C; Berger P; Guilleminault L
    Allergy; 2017 Dec; 72(12):1953-1961. PubMed ID: 28517027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.